Celgene Reports Results of CC-486 in P-III QUAZAR AML-001 Study as Maintenance Therapy for Acute Myeloid Leukemia

 Celgene Reports Results of CC-486 in P-III QUAZAR AML-001 Study as Maintenance Therapy for Acute Myeloid Leukemia

Celgene’s Pomalyst (pomalidomide)-Based Triple Regimen Receive Health Canada’s Approval for Multiple Myeloma

Shots:

  • The P-III QUAZAR AML-001 study involves assessing of CC-486 (300mg) as maintenance therapy vs PBO + SoC in 472 patients in a ratio (1:1) with AML who achieved first CR with incomplete blood count recovery (CRi) with induction chemotherapy (with/out consolidation)
  • The P-III QUAZAR AML-001 study resulted in meeting its 1EPs & 2EPs i.e, improvement in OS & RFS, safety, tolerability, healthcare resource utilization and patient-reported outcomes per the FACIT-Fatigue Scale and EQ-5D questionnaire respectively
  • CC-486 is an analog of cytidine nucleoside, incorporated into DNA & RNA act by causing DNA hypomethylation and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow with its anticipated regulatory submissions in H1’20

Click here to­ read full press release/ article | Ref: Celgene | Image: Bio Online

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post